Roche's giredestrant 加上 Everolimus 提高了高级乳腺癌患者在CDK4/6治疗后存活率,试验结果良好,没有新的安全顾虑。 Roche's giredestrant plus everolimus improved survival in advanced breast cancer patients post-CDK4/6 therapy, with positive trial results and no new safety concerns.

罗氏公司宣布了对口服药物giredestrant与everolimus联合的III期试验的积极结果,该试验显示,在经过CDK4/ 6抑制剂治疗后进展的ER阳性晚期乳腺癌患者中,无进展生存率有所改善. Roche announced positive Phase III trial results for giredestrant, an oral drug, combined with everolimus, showing improved progression-free survival in advanced ER-positive breast cancer patients who progressed after CDK4/6 inhibitor treatment. evERA试验在整体上和ESR1组合的分组中都达到了其主要终点,优于标准内分泌疗法加永生素。 The evERA trial met its primary endpoints in both overall and ESR1-mutated subgroups, outperforming standard endocrine therapy plus everolimus. 组合是经过良好调整的,没有出现任何新的安全问题。 The combination was well-tolerated with no new safety issues. Roche计划向卫生当局提交数据供可能批准,目的是为选择有限的病人提供一种新的治疗选择。 Roche plans to submit data to health authorities for potential approval, aiming to provide a new treatment option for patients with limited choices.